Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Biocartis SA

Biocartis is a commercial stage molecular diagnostics company that develops diagnostics technology platforms for mult... read more Featured Products: More products

Download Mobile App




Rapid Genomic Profiling of Colon Cancers Improves Therapy Selection

By LabMedica International staff writers
Posted on 09 Jul 2020
Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine (colon) or rectum. More...
Colorectal cancer is the third leading cause of cancer in both men and women in the USA. Most colorectal cancers develop from polyps. Removal of colon polyps can aid in the prevention of colorectal cancer.

Treatment of colorectal cancer depends on the location, size, and extent of cancer spread, as well as the health of the patient. Management of colorectal cancer warrants mutational analysis of KRAS/NRAS when considering anti–epidermal growth factor receptor therapy and BRAF testing for prognostic stratification.

Scientists at the Geisel School of Medicine (Lebanon, NH, USA) and their colleagues enrolled 874 colorectal cancer cases from 20 laboratories between November 2017 and December 2018. The teams compared a new cartridge-based laboratory testing device called the Idylla automated system (Biocartis US, Inc, Jersey City, NJ, USA) using the KRAS and NRAS-BRAF cartridges to current standard-of-care testing methods.

The multicenter teams reported that the average turnaround time for test results could be cut by more than 65% from 15 days to five days, with some results available in a single day. The significant decrease in wait time means patients can begin appropriate treatments for colorectal cancer much sooner. The simplicity and ease of use of the new technology compared with other molecular techniques also makes it suitable for integration into clinical laboratories of any size, including those that may not have much molecular expertise.

In collecting the data, the study also addressed the use of minimal tissue from the patient sample. Gregory J. Tsongalis, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “One of the study sites included several 1-mm tissue biopsy samples, showing that even smaller tissue-based specimens can be successfully analyzed by Idylla. Our results are in line with findings of other studies showing successful analyses using very small tissue amounts, including those deemed too small for standard molecular testing methods.”

The authors concluded that the described cartridge-based system offers rapid and reliable testing of clinically actionable mutation in colorectal cancer specimens directly from formalin-fixed, paraffin-embedded tissue sections. Its simplicity and ease of use compared with other molecular techniques make it suitable for routine clinical laboratory testing. The study was published on June 11, 2020 in the American Journal of Clinical Pathology.





New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.